Conatus Pharmaceuticals to Relocate Corporate Headquarters

Conatus Pharmaceuticals to Relocate Corporate Headquarters

SAN DIEGO, July 7, 2014 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc.
(Nasdaq:CNAT), a biotechnology company focused on the development and
commercialization of novel medicines to treat liver disease, today announced
that it will relocate the company's corporate headquarters to a new leased
facility in northern San Diego at 16745 W Bernardo Drive, Suite 200, San
Diego, CA 92127. All Conatus phone numbers will change as a result of the
relocation. Email addresses will not change.

Current phone numbers will remain effective until noon PDT on Thursday, July
24, 2014, when the company will close for the move. New phone numbers will be
available on the company's website when the company reopens at its new
location on Monday, July 28, 2014.

About Conatus Pharmaceuticals Inc.

Conatus is a biotechnology company focused on the development and
commercialization of novel medicines to treat liver disease. Conatus is
developing emricasan as a first-in class, orally active caspase protease
inhibitor designed to reduce the activity of enzymes that mediate inflammation
and cell death, or apoptosis. Conatus believes that by reducing the activity
of these enzymes, emricasan has the potential to interrupt the progression of
liver disease. For additional information, please visit www.conatuspharma.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of
Section 21E of the Securities Exchange Act of 1934, as amended. All statements
other than statements of historical facts contained in this press release,
including statements regarding anticipated clinical development plans and
proposed activity of emricasan in patients with liver disease, are
forward-looking statements. In some cases, you can identify forward-looking
statements by terms such as "may," "will," "should," "expect," "plan,"
"anticipate," "could," "intend," "target," "project," "contemplates,"
"believes," "estimates," "predicts," "potential" or "continue" or the negative
of these terms or other similar expressions. These forward-looking statements
speak only as of the date of this press release and are subject to a number of
risks, uncertainties and assumptions, including those described in Conatus'
prior press releases and the periodic reports it files with the Securities and
Exchange Commission. The events and circumstances reflected in Conatus'
forward-looking statements may not be achieved or occur and actual results
could differ materially from those projected in the forward-looking
statements. Except as required by applicable law, Conatus does not plan to
publicly update or revise any forward-looking statements contained herein,
whether as a result of any new information, future events, changed
circumstances or otherwise.

CONTACT: INVESTORS
         Alan Engbring, Conatus Pharmaceuticals
         (858) 457-7237, aengbring@conatuspharma.com
        
         MEDIA
         Mariesa Kemble, Sam Brown Inc.
         (608) 850-4745, mariesakemble@sambrown.com
 
Press spacebar to pause and continue. Press esc to stop.